AUGUSTA, Maine — Maine will receive about $13,000 as part of a $612 million national settlement with Amgen Inc. over allegations that the pharmaceutical company illegally promoted and manipulated the prices of some of its drugs.
Maine will receive a total of $13,313, according to a press release from the Maine Attorney General’s Office on Thursday.
The federal government alleged that Amgen used illegal marketing practices to promote sales of the drugs Aranesp, Enbrel and Neulasta and arranged kickbacks to health care providers for choosing six of the company’s drugs for Medicaid recipients. Amgen also knowingly reported inaccurate prices for some drugs, the government alleged.
The settlement money will compensate Medicaid, Medicare and other federal health care programs for harm suffered as a result of Amgen’s conduct.